Amarantus BioScience Holdings, Inc. (AMBS) to Commence Evaluation of the LymPro Test as a Diagnostic and Prognostic
Biotechnology company Amarantus BioScience Holdings has announced plans to evaluate its LymPro Test as a potential diagnostic and prognostic for chronic traumatic encephalopathy (CTE), which is a progressive degenerative disease of the brain found in athletes and others with a history of repetitive brain trauma. Just as the scientific basis of cell-cycle dysfunction supports the development of the LymPro Test as a diagnostic blood test for Alzheimer’s disease, the same principles may potentially be utilized in diagnosing CTE in individuals who have endured multiple head injuries. The test may also preventatively identify those predisposed to developing CTE before they ever…